First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions
- Fallopian Tube Carcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- FIGO Stage III Ovarian Cancer
- FIGO Stage IIIA Ovarian Cancer
- FIGO Stage IIIA1 Ovarian Cancer
- FIGO Stage IIIA1(i) Ovarian Cancer
- FIGO Stage IIIA1(ii) Ovarian Cancer
- FIGO Stage IIIA2 Ovarian Cancer
- FIGO Stage IIIB Ovarian Cancer
- FIGO Stage IIIC Ovarian Cancer
- FIGO Stage IVA Ovarian Cancer
- FIGO Stage IVB Ovarian Cancer
- Malignant Ovarian Brenner Tumor
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Primary Peritoneal Carcinoma
- Primary Peritoneal Serous Adenocarcinoma
Interventions
- BIOLOGICAL: Bevacizumab
- DRUG: Carboplatin
- DRUG: Paclitaxel
Sponsor
M.D. Anderson Cancer Center
Collaborators